Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00170911
Status:
COMPLETED
Last Update Posted:
2011-11-02
First Post:
2005-09-09
Brief Title:
Efficacy and Safety of AAE581 in Postmenopausal Women With OsteopeniaOsteoporosis
Sponsor:
Novartis Pharmaceuticals
Organization:
Novartis
Study Overview
Official Title:
Efficacy and Safety of AAE581 in Postmenopausal Women With OsteopeniaOsteoporosis
Status:
COMPLETED
Status Verified Date:
2011-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
AAE581 is a specific inhibitor of the cysteine protease cathepsin K This trial is designed to provide detailed information about the effects efficacy and safety of AAE581 on Bone Mineral Density
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None